Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT07670702
PHASE3

An Evaluation of the Long-Term Safety and Efficacy of TSND-201 for the Treatment of PTSD

Sponsor: Transcend Therapeutics

View on ClinicalTrials.gov

Summary

This study is evaluating the long-term safety and efficacy of TSND-201 in adults with PTSD. Participants that have completed a double-blind clinical trial with TNSD-201 for PTSD will be invited to participate in this open-label extension trial. Each participant will be able to receive up to three Treatment Courses over the duration of the study (up to 48 weeks). Each Treatment Course includes 4 dosing sessions, spaced one week apart.

Official title: A Phase 3 Open-Label Extension Study to Assess the Long-term Safety and Efficacy of TSND-201 for the Treatment of PTSD

Key Details

Gender

All

Age Range

Any - Any

Study Type

INTERVENTIONAL

Enrollment

300

Start Date

2026-06

Completion Date

2029-01

Last Updated

2026-06-26

Healthy Volunteers

No

Interventions

DRUG

TSND-201

TSND-201 capsules, given orally; where a course of treatment includes dosing with TSND-201 once a week for four consecutive weeks

Locations (1)

CNS Healthcare

Orlando, Florida, United States